SCHEMBL3170264

SCHEMBL3170264

Nc1cnc2ccccc2c1NCCOCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
PKM P14618 1/20 0.46
KDM4E B2RXH2 6/20 0.46
POLB P06746 3/20 0.46
GAA P10253 3/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
RAD52 P43351 2/20 0.46
RAB9A P51151 2/20 0.46
MITF O75030 2/20 0.46
TTR P02766 1/20 0.46
GLA P06280 1/20 0.46
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
KCNH3 Q9ULD8 2/20 0.41
LATS1 O95835 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493232 0.86 KDM4E (0.61) KMT2AMEN1PKMKDM4EPOLB
Hydrochloric Acid SCHEMBL10728396 0.85 POLB (0.59) KMT2AMEN1PKMKDM4EPOLB
SCHEMBL10728537 0.83 POLB (0.63) KMT2AMEN1PKMKDM4EPOLB
SCHEMBL10123175 0.82 KMT2A (0.41) KMT2AMEN1PKMKDM4EPOLB
SCHEMBL4313700 0.82 POLB (0.57) KMT2AMEN1PKMKDM4EPOLB
SCHEMBL6800384 0.81 GBA1 (0.46) KMT2AMEN1PKMKDM4EPOLB
SCHEMBL12665011 0.80 POLB (0.44) KMT2AMEN1PKMKDM4EPOLB
SCHEMBL1039304 0.80 MEN1 (0.44) KMT2AMEN1PKMGAARAB9A
SCHEMBL3168206 0.79 KMT2A (0.45) KMT2AMEN1PKMKDM4EPOLB
SCHEMBL1950779 0.79 NPSR1 (0.39) KMT2AMEN1RAB9ABCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673932-B2 Oxime substituted imidazo-containing compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-03-18 US disclosed
US-7648997-B2 Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide COLEY PHARMACEUTICAL GROUP, INC. (US) 2010-01-19 US disclosed
US-20080114019-A1 Hydroxylamine Substituted Imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-05-15 US disclosed
US-20070066639-A1 Oxime substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114019-A1 Hydroxylamine Substituted Imidazoquinolines IFNG, IRF3, IL2 KMT2A 1181/4885MEN1 4072/4885PKM 1971/4885
US-20070066639-A1 Oxime substituted imidazoquinolines IFNG, IRF3, IL2 KMT2A 2150/4885MEN1 4159/4885PKM 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.